Navigation Links
Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
Date:6/22/2008

hese events are key aspects of identifying and minimizing them, Lilly has proposed a plan for managing PDSS risks that is comprised of a detailed product label, extensive healthcare provider training before product availability and an ongoing educational program.

About HGKB (160-week Interim Results of Open-label Extension Trial)

Adult patients with schizophrenia or schizoaffective disorder (n=931) were enrolled in this ongoing open-label trial of olanzapine LAI following participation in one of three randomized, controlled studies of olanzapine LAI. At study onset, patients received flexibly-dosed olanzapine LAI at intervals of approximately two to four weeks.

At the time of analysis, all patients had had the opportunity to be in the study for at least one year of open-label treatment; some had been enrolled for up to three years of treatment.

Treatment response was measured by the Clinical Global Impression Severity of Illness (CGI-S) scale, which examined severity of illness, global improvement and efficacy. Baseline-to-endpoint mean change on the CGI-S was -0.16, from a baseline of 2.92.

At 160 weeks, the discontinuation rate was low (39.6 percent). The most common reasons for discontinuation were that a patient withdrew consent (20.1 percent), experienced an adverse event (6.3 percent) or was lost to follow up (5.6 percent).

Adverse events reported in 5 percent or more of patients were increased weight, insomnia, somnolence, anxiety, headache, and nasopharyngitis. The mean weight change of study participants was an increase of 1.4 kilograms, with 28.1 percent of patients experiencing an increase of 7 percent or more in weight.

The percentage of patients with a fasting glucose increase from normal to high at any time was 4.7 percent. The percentage of patients with a random total cholesterol increase from normal to high at any time was 5.2 percent. The percentage of patients with a random triglycerides increase fr
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
2. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
3. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
4. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
5. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
6. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
7. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
8. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
9. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
10. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... -- A German Diabetes Center clinical study found that ... enriches human gut microbiota and modifies gut production of ... daily administration of Nutraceutix,s L. reuteri strain ... tract ® delivery technology that protects live ... to the intestinal tract. The randomized, double-blind, ...
(Date:7/28/2015)... The Physician-Patient Alliance for Health & Safety ... Surviving Your Hospital Stay ." "Help us ... of these patients went home from hospital," said ... referring to the patient stories presented at ... Promote Continuous Monitoring of Patients on Opioids (shown ...
(Date:7/28/2015)... TAMPA, Fla. , July 28, 2015  For ... by their researchers, physicians and other inventors can be ... to market is difficult, and successes are rare. ... wants to change that. Medical Device ... technology licensed from universities, hospitals and physicians. MDI develops, ...
Breaking Medicine Technology:Nutraceutix's L. reuteri Probiotic Clinically Proven to Modulate Gut Insulin Metabolism 2Surviving Your Hospital Stay: Physician-Patient Alliance for Health & Safety Launches Fundraising for Patient Safety 2Medical Device Investments To Become Center Of Excellence For The Commercialization Of Innovative Medical Technologies 2
... Significance, FRAZER, Pa., May 01, 2007 /PRNewswire-FirstCall/ ... presented today at the 59th Annual,Meeting of ... highlights,data demonstrating that FENTORA(R) (fentanyl buccal tablet) ... pain in patients,with neuropathic pain who are ...
... Inc. (NYSE:DNA),and Biogen Idec, Inc. (Nasdaq:BIIB) announced ... study of Rituxan(R) (rituximab) in,patients with relapsing-remitting ... American Academy of Neurology annual meeting,held in ... targets and,selectively depletes CD20-positive B-cells., "There remains ...
Cached Medicine Technology:Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 2Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 3Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 4Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 5Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 6Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 7Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6
(Date:7/28/2015)... ... , ... Talking About Your Product Pipeline:, How FDA and SEC Regulate Life ... http://www.fdanews.com/productpipeline , When a company has a product in development, whether drug, ... tightly regulated by the FDA. , At the same time, the SEC requires that ...
(Date:7/28/2015)... West Jordan, Utah (PRWEB) , ... July 28, ... ... Medical Center West Valley Campus have received the Get With The Guidelines®-Stroke Gold ... Association for excellence in patient care and outcomes. , The Get With ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... products, announces Skimmer Helper, a household invention that cleans pools efficiently - minus ... billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "It ...
(Date:7/28/2015)... ... July 28, 2015 , ... World ... Lost and Found, a breakthrough technological invention. It is a wearable personal ... consumer electronic industry reached a record high of $211.3 billion in 2014," says ...
(Date:7/28/2015)... ... ... Dr. Edward Buckingham and Buckingham Center for Facial Plastic Surgery, is ... to Austin from Philadelphia, Dr. Roy will be completing his Fellowship in facial plastic ... by the American Academy of Facial Plastic and Reconstructive Surgery. , Since 1969, ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Talking About Your Product Pipeline: How FDA and SEC Regulate Life Sciences Communications Webinar, Aug. 19, 2015 2Health News:FDAnews Announces — Talking About Your Product Pipeline: How FDA and SEC Regulate Life Sciences Communications Webinar, Aug. 19, 2015 3Health News:FDAnews Announces — Talking About Your Product Pipeline: How FDA and SEC Regulate Life Sciences Communications Webinar, Aug. 19, 2015 4Health News:Jordan Valley Medical Center and Jordan Valley Medical Center West Valley Campus Receive Stroke Award 2Health News:Jordan Valley Medical Center and Jordan Valley Medical Center West Valley Campus Receive Stroke Award 3Health News:10 Fascinating Things You Never Knew About Swimming Pools Is Introduced by World Patent Marketing and Skimmer Helper 2Health News:10 Fascinating Things You Never Knew About Swimming Pools Is Introduced by World Patent Marketing and Skimmer Helper 3Health News:10 Fascinating Things You Never Knew About Swimming Pools Is Introduced by World Patent Marketing and Skimmer Helper 4Health News:10 Fascinating Things You Never Knew About Swimming Pools Is Introduced by World Patent Marketing and Skimmer Helper 5Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 2Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 3Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 4Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 5Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 2Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 3
... were more likely to report a family history of ... who did not have prostate// cancer, according to researchers ... ,The data were part of the Flint Men’s Health ... who live in Flint, Mich. The Flint Men's Health ...
... is not well and cannot attend court the next three ... ago following chest pain. ,"He is not well. I ... court proceedings for the next three days," said Shakti Gupta, ... Sciences (AIIMS). ,According to Gupta, six heart ...
... boost its health tourism industry in the US, says an ... of Kerala Associations in North America (Fokana), which has members ... Kerala governments to promote the state as a destination for ... attention of the entire US. If Kerala does it, there ...
... Tuberculosis, a highly communicable disease, has turned out to be ... affected nations in the world. It is estimated //that nearly ... ,This has raised the concern of Kenyan doctors and ... label tuberculosis as a national debacle and formulate special laws ...
... to see that a robust and effective legislation which ... life is brought into force within the next six ... AIDS Day organized by Parliamentarians Forum on HIV/AIDS and ... following suggestions to MPs, research laboratories, the Pharma industry ...
... the Western Pacific region to take action to curb HIV. ... in Aids infection with figures escalating to 8.6 million. Only ... year. WHO has issued the call to governments to intervene ... virus. ,Mr. Shigeru Omi, the director for ...
Cached Medicine News:Health News:African-Americans With Prostate Cancer More Likely to Have Family History 2Health News:President Urges to Avoid Discrimination Against AIDS Patients 2
Galt Skull Trephine with adjustable centering point and detachable cross-bar handle, 19.0 mm....
Greenberg micro instrument holder is a flexbar arm used to hold micro instruments used repeatedly within retracted fields. Holds instruments with shafts up to 1/8 in diameter....
Length-9 (229 mm) Tapered retractor blades. 1/16 x 1/4 (1.6 mm x 19 mm)....
Kit is supplied with four secondary bars. Secondary bars attach to primary bar. Length 12 (305 mm)....
Medicine Products: